The National Pharmaceutical Council's research helps to inform many critical health care policy debates and supports the organization's overall goal of achieving the best patient outcomes in the most efficient way possible. Over the years, the issues we have focused on have evolved along with the changes in the health care environment and pharmaceutical industry. NPC’s current research examines the most pressing topics in comparative effectiveness research (CER), individual treatment effects, and the optimal role and value of pharmaceuticals in emerging payment and delivery models.
Comparative effectiveness research (CER) is the conduct and synthesis of research comparing the benefits and harms of different interventions and strategies to prevent, diagnose, treat and monitor health conditions.Learn More
There are a variety of factors that make patients different and affect how they may respond to a certain treatment. While the “average patient” may respond best to a particular treatment, some patients may experience little to no benefit from it, so other treatment options may...Learn More
Investing in worker health and, in the process, managing chronic health conditions and preventing disability and serious illness, can lead to both an increase in the quality of living for employees and cost savings for employers through productivity gains.
In an environment where nearly every entity in the health care delivery business is concerned about costs and spending, the issue of quality can sometimes be overshadowed. In designing benefits and delivering care, it is critical that providers and payers stay rooted in what the...Learn More
Why are some health treatments covered by insurance, while others are not? Why do some treatments have higher copays than others? These considerations are a result of how health benefits are designed.
NPC’s ongoing research efforts work to define key elements of value and demonstrate their significance to health care stakeholders, while also broadly identifying both the barriers that prevent the full value generated by biopharmaceuticals from being realized and potential...Learn More